Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
22.52
Dollar change
+0.03
Percentage change
0.13
%
Index- P/E34.80 EPS (ttm)0.65 Insider Own2.76% Shs Outstand302.79M Perf Week-1.27%
Market Cap6.64B Forward P/E14.51 EPS next Y1.55 Insider Trans-0.19% Shs Float286.65M Perf Month-5.02%
Income207.76M PEG1.83 EPS next Q0.23 Inst Own89.59% Short Float2.38% Perf Quarter0.18%
Sales1.83B P/S3.63 EPS this Y91.37% Inst Trans-1.96% Short Ratio3.00 Perf Half Y5.48%
Book/sh7.48 P/B3.01 EPS next Y24.78% ROA6.85% Short Interest6.83M Perf Year17.54%
Cash/sh3.38 P/C6.67 EPS next 5Y19.00% ROE8.74% 52W Range18.08 - 24.34 Perf YTD-6.13%
Dividend Est.- P/FCF22.67 EPS past 5Y-21.77% ROI8.47% 52W High-7.48% Beta0.58
Dividend TTM- Quick Ratio3.30 Sales past 5Y17.31% Gross Margin96.04% 52W Low24.56% ATR (14)0.53
Dividend Ex-Date- Current Ratio3.34 EPS Y/Y TTM15.07% Oper. Margin9.34% RSI (14)42.80 Volatility2.39% 2.20%
Employees1310 Debt/Eq0.10 Sales Y/Y TTM13.60% Profit Margin11.35% Recom1.73 Target Price26.73
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q392.82% Payout0.00% Rel Volume1.02 Prev Close22.49
Sales Surprise-0.14% EPS Surprise17.54% Sales Q/Q13.15% EarningsApr 30 AMC Avg Volume2.28M Price22.52
SMA20-3.56% SMA500.66% SMA2003.57% Trades Volume2,329,664 Change0.13%
Date Action Analyst Rating Change Price Target Change
Apr-11-24Downgrade Barclays Overweight → Equal Weight $25
Dec-19-23Initiated BTIG Research Buy $27
Dec-15-23Initiated Citigroup Buy $31
Sep-26-23Initiated H.C. Wainwright Buy $28
Aug-22-23Reiterated Oppenheimer Outperform $25 → $29
Aug-08-23Initiated SVB Securities Market Perform $18
Jul-11-23Resumed Morgan Stanley Equal-Weight $21
May-10-23Resumed Piper Sandler Overweight $28
Mar-09-23Initiated Wells Fargo Overweight $23
Jan-26-23Initiated Credit Suisse Outperform $29
Apr-16-24 04:05PM
Mar-28-24 08:13AM
Mar-23-24 05:06AM
Mar-17-24 08:50AM
Mar-08-24 09:38AM
08:15AM Loading…
08:15AM
Mar-07-24 11:31AM
10:08AM
Mar-06-24 04:45PM
Mar-04-24 07:06PM
Mar-02-24 05:06AM
Feb-27-24 04:05PM
08:00AM
Feb-26-24 07:42AM
Feb-23-24 01:11PM
08:00AM Loading…
Feb-19-24 08:00AM
Feb-14-24 08:30AM
01:47AM
Feb-13-24 08:00AM
Feb-12-24 09:35AM
Feb-10-24 05:06AM
Feb-09-24 09:35AM
Feb-08-24 06:50PM
09:35AM
Feb-07-24 07:01PM
01:13PM
10:47AM
09:45AM
Feb-06-24 08:45PM
06:30PM
05:25PM Loading…
05:25PM
05:01PM
04:33PM
04:05PM
Feb-01-24 04:05PM
Jan-30-24 10:00AM
Jan-29-24 09:40AM
Jan-25-24 08:00AM
Jan-23-24 04:05PM
Jan-22-24 05:00PM
Jan-21-24 01:16PM
Jan-19-24 11:21AM
Jan-18-24 04:05PM
04:00PM
Jan-17-24 11:29AM
Jan-11-24 09:40AM
Jan-08-24 04:40PM
12:43PM
06:12AM
Jan-07-24 04:00PM
Jan-02-24 04:05PM
Dec-19-23 10:16AM
Dec-12-23 08:54AM
Dec-07-23 04:05PM
Dec-05-23 01:51PM
Dec-04-23 07:26PM
08:02AM
08:00AM
Dec-01-23 11:32AM
Nov-29-23 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
Nov-08-23 05:24PM
05:19AM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
12:30AM
Nov-01-23 07:00PM
06:05PM
04:05PM
Oct-30-23 10:00AM
Oct-28-23 05:06AM
Oct-27-23 04:58AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
08:30AM
Oct-22-23 02:30AM
Oct-19-23 06:51PM
08:15AM
Oct-18-23 04:05PM
08:30AM
Oct-12-23 11:40AM
Oct-09-23 02:03AM
Oct-02-23 09:49AM
Sep-20-23 02:15PM
Sep-18-23 09:16AM
Sep-16-23 05:06AM
Sep-15-23 10:23AM
Sep-13-23 11:23AM
08:29AM
Sep-12-23 08:00AM
Sep-11-23 12:31PM
Sep-08-23 11:30AM
Sep-07-23 08:43AM
Sep-06-23 09:33AM
Sep-05-23 11:40AM
09:40AM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorMar 21 '24Option Exercise19.5723,491459,71954,908Mar 25 07:31 PM
Garber Alan MDirectorMar 21 '24Sale24.0119,205461,11235,703Mar 25 07:31 PM
Haley Patrick J.EVP, CommercialFeb 23 '24Sale21.4547,0201,008,579384,866Feb 27 06:58 PM
JOHNSON DAVID EDWARDDirectorFeb 21 '24Buy20.70190,0003,932,7341,100,730Feb 22 05:08 PM
Haley Patrick J.EVP, CommercialDec 14 '23Option Exercise16.2950,000814,500357,687Dec 14 07:56 PM
Haley Patrick J.EVP, CommercialDec 14 '23Sale23.3550,0001,167,500307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 13 '23Sale23.0125,000575,250533,345Dec 14 07:55 PM
Haley Patrick J.EVP, CommercialDec 12 '23Sale22.5014,149318,352307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 04 '23Sale22.0625,000551,500558,345Dec 04 06:22 PM
Hessekiel JeffreyEVP, General Counsel & SecNov 30 '23Sale22.0125,000550,250583,345Dec 04 06:22 PM
JOHNSON DAVID EDWARDDirectorNov 27 '23Buy21.61120,4092,602,038910,730Nov 29 04:30 PM
JOHNSON DAVID EDWARDDirectorNov 27 '23Sale21.61120,4092,602,038790,321Nov 29 04:30 PM
Aftab DanaCSO/EVP Disc & Trans ResearchAug 30 '23Sale22.474,600103,362399,943Sep 01 08:15 PM
MORRISSEY MICHAELPresident and CEOAug 28 '23Option Exercise15.31360,0005,511,600945,496Aug 30 09:48 PM
Senner Christopher J.EVP and CFOAug 04 '23Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 04 '23Sale20.6860,0001,240,800571,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03 '23Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03 '23Sale20.5160,0001,230,600571,631Aug 07 09:20 PM
Haley Patrick J.EVP, CommercialAug 03 '23Sale20.6730,553631,531285,467Aug 07 08:24 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01 '23Option Exercise14.7455,710821,165627,686Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01 '23Sale19.6355,7101,093,587571,976Aug 03 08:02 PM